Ainos Inc, a pioneering healthcare firm based in San Diego that specializes in advanced AI-enhanced point-of-care diagnostics and low-dose interferon therapies, has disclosed that it has entered into a crucial memorandum of understanding (MoU) with Taiwan Tanabe Seiyaku Co, Ltd. This company, a subsidiary of Japan’s Mitsubishi Tanabe Pharma Corporation, brings substantial expertise in pharmaceutical development and manufacturing to the collaboration.
The goal of this partnership is to bolster both the production process and the market introduction of Ainos’ innovative medication for Sjögren’s syndrome, known as Veldona, within Taiwan. Both entities will negotiate and finalize the terms of their joint efforts based on the MoU.
Sjögren’s syndrome, which affects millions globally, is an autoimmune condition with a notable shortfall of effective treatments. With the aging of the global population and burgeoning recognition of the disease, there is a sharply increasing need for medical solutions. Market forecasts indicate that the global demand for Sjögren’s syndrome treatments will multiply into billions of dollars over the coming five years. Ainos aspires that Veldona will successfully address this market need by offering a novel and necessary solution for countless sufferers.
Ainos has invested considerable time into developing therapies for Sjögren’s syndrome, honing Veldona—a low-dose oral interferon-alpha—which has demonstrated strong promise in clinical evaluations. Studies reveal that Veldona significantly improves patient symptoms, enhances life quality, and effectively manages disease advancement. The drug’s high tolerability and safety record set a promising stage for larger-scale international clinical trials.
As part of Mitsubishi Tanabe Pharma, Taiwan Tanabe Seiyaku brings a wealth of pharmaceutical development and market expansion expertise. The collaboration aims for Taiwan Tanabe Seiyaku to work with Ainos in the production and promotion of Veldona to satisfy market demands. The specifics of their responsibilities and the framework for their joint initiative will be further clarified under the MoU’s terms.
This alliance with Taiwan Tanabe Seiyaku is poised to hasten Veldona’s introduction to the global market, ensuring that patients receive the medication efficiently. A formal contract will delineate the precise roles and obligations of the partners, setting the stage for enduring success. Ainos expects that with the accumulation of clinical evidence and the expansion of Veldona’s market presence, the drug will assert its status as a primary treatment for Sjögren’s syndrome. Furthermore, Veldona’s success could lead to more opportunities in treating other autoimmune disorders, thereby boosting the company’s market value and growth prospects.